Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 3/20 | 0.31 |
| ▸ | HTR1D | P28221 | 3/20 | 0.31 |
| ▸ | HTR2A | P28223 | 3/20 | 0.31 |
| ▸ | HTR1A | P08908 | 2/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2891301 | 0.88 | KCNJ1 (0.35) | KCNJ1DRD2HTR1DHTR2AHTR1A | |
| SCHEMBL298657 | 0.87 | KCNJ1 (0.38) | KCNJ1DRD2HTR2A | |
| SCHEMBL2729498 | 0.85 | KCNJ1 (0.36) | KCNJ1DRD2HTR1DHTR2AHTR1A | |
| SCHEMBL286987 | 0.80 | MTNR1B (0.40) | DRD2HTR1DHTR2AHTR1ADRD4 | |
| SCHEMBL2732161 | 0.80 | KCNJ1 (0.37) | KCNJ1DRD2HTR1DHTR2AHTR1A | |
| SCHEMBL300048 | 0.76 | KCNJ1 (0.35) | KCNJ1DRD2HTR1DHTR2AHTR1A | |
| SCHEMBL2894905 | 0.75 | MEN1 (0.35) | KCNJ1DRD2HTR1DHTR2AHTR1A | |
| SCHEMBL296709 | 0.68 | CYP1A2 (0.39) | — | |
| SCHEMBL2733021 | 0.66 | TERT (0.41) | — | |
| SCHEMBL2733149 | 0.66 | KCNJ1 (0.35) | KCNJ1DRD2HTR1DHTR2AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427444-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2015-12-16 | — | — | EP | disclosed |
| US-9018211-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140142115-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8673920-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20100286123-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142115-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | KCNJ1 2/4885DRD2 2601/4885HTR1D 897/4885 |
| US-20100286123-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | KCNJ1 2/4885DRD2 2601/4885HTR1D 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.